iGMDRD792

Canonical SMILES: CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C.Br

InChI: InChI=1S/C17H23NO2.BrH/c1-13-17(2,3)14-9-6-7-10-15(14)18(13)12-8-4-5-11-16(19)20;/h6-7,9-10H,1,4-5,8,11-12H2,2-3H3,(H,19,20);1H

InChI Key: SVMKEDBUSSWSFY-UHFFFAOYSA-N

Loading, please wait...
Standard Name
Pubchem CID
Drug Status
Drug Type
Standard NameCetuximab
Pubchem CID91820600
Drug StatusAlone
Drug TypeSmall Molecule

Drug Targets:

EGFR

Drug Pathways:

EGFR signaling

Drug-model tissue-cancer distribution: Bubble Plot

Drug-gene pathway enrichments

Drug-gene GO enrichments

Drug-Gene: Aster Plot


Loading, please wait...
Gene ID
Gene Name
Model Num.
3845 KRAS 32
4907 NT5E 1
6597 SMARCA4 1
5079 PAX5 1
Showing 1 to 4 of 28 rows rows per page

Gene in drug-gene network: Network Plot

tipifarnib-P2tipifarnib-P2cytochalasin.Bcytochalasin.BTamoxifenTamoxifenSepantroniumSepantroniumAM-580AM-580nutlin 3nutlin 3PAX5PAX5MET inhibitorsMET inhibitorsPF-2341066PF-2341066neopeltolideneopeltolideEGFR inhibitor 1st genEGFR inhibitor 1st genCHIR-99021CHIR-99021lapatinib in HER2-amplifiedlapatinib in HER2-amplifiedCapmatinibCapmatinibABT737ABT737PanitumumabPanitumumabVX-680VX-680pevonedistatpevonedistatVemurafenibVemurafenibXL-184XL-184trastuzumab alonetrastuzumab aloneRNMTRNMTTJP2TJP2PI-103PI-103BMS-754807BMS-754807Compound 44Compound 44ciclosporinciclosporinitraconazoleitraconazoleCompound 110Compound 110Merck60Merck60SB225002SB225002bistramide Abistramide AnakiterpiosinnakiterpiosinYK.4.279YK.4.279(-)-gallocatechin-3-O-gallate(-)-gallocatechin-3-O-gallateBET inhibitorsBET inhibitorserastinerastinCD437CD437kahalalide Fkahalalide FMYCMYCselumetinib in BRAF mutant tumorsselumetinib in BRAF mutant tumorstensirolimus plus chemotherapytensirolimus plus chemotherapyISX-9ISX-9BevacizumabBevacizumabEverolimusEverolimusErlotinibErlotinibLY 2183240LY 2183240mTOR inhibitorsmTOR inhibitorsAR-42AR-42Nsc 632839Nsc 632839Imatinib MesylateImatinib MesylateFAK inhibitorsFAK inhibitorsPAK inhibitorsPAK inhibitorsNF2NF2BMS-536924BMS-536924navitoclaxnavitoclaxPARP inhibitorsPARP inhibitorsSirolimusSirolimusMAGI1MAGI1IdarubicinIdarubicinBX-795BX-795manumycin.Amanumycin.AParthenolideParthenolideBI-2536BI-2536Compound.1541ACompound.1541Aleucascandrolide Aleucascandrolide ANSC141540NSC141540zebularinezebularineCompound.23.citrateCompound.23.citrate4-methylfasudil4-methylfasudilEGFEGFMEK inhibitorsMEK inhibitorssalermidesalermideCobimetinibCobimetinibSCH-529074SCH-529074DC-45-A2DC-45-A2SorafenibSorafenibBRAF inhibitorsBRAF inhibitorsEGFR TKIsEGFR TKIsCHEMBL1434137CHEMBL1434137SB590885SB590885pan-RAF inhibitorspan-RAF inhibitorsPLX-4720PLX-4720DabrafenibDabrafenibRefametinibRefametinibTrametinibTrametinibBRAFBRAFAnti-EGFR Monoclonal AntibodyAnti-EGFR Monoclonal AntibodyEGFR mAb inhibitorEGFR mAb inhibitorEREGEREGPTP4A3PTP4A3LY3023414LY3023414GSK2636771GSK2636771BRD63610BRD63610BIX01294BIX01294VER 155008VER 155008OlaparibOlaparibPI3K pathway inhibitorsPI3K pathway inhibitorsMK-2206MK-2206AZD8186AZD8186GSK690693GSK690693PTENPTENRITARITAAfatnibAfatnibCompound.7d.cisCompound.7d.cisavrainvillamideavrainvillamideSCHEMBL2608041SCHEMBL2608041BRD7137BRD7137VHLVHLEGFR inhibitor 3rd genEGFR inhibitor 3rd genGefitnibGefitnibGW-405833GW-405833NSC95397NSC95397DacomitinibDacomitinibirreversible EGFR TKIsirreversible EGFR TKIsGMX1778GMX1778OsimertinibOsimertinibHSP90 inhibitorsHSP90 inhibitorsMEK inhibitors (alone or in combination)MEK inhibitors (alone or in combination)EGFREGFRELCPKELCPKGW-843682XGW-843682XparbendazoleparbendazoleBRD4354BRD43543-chloro-L-alanine3-chloro-L-alanineteniposideteniposideLexibulinLexibulinCHM-1CHM-1SMAD4SMAD4BicalutamideBicalutamidePFI-1PFI-1NSC87877NSC87877CX-5461CX-5461LenalidomideLenalidomideVX-702VX-702Avagacestat (BMS-708163)Avagacestat (BMS-708163)JNK.Inhibitor.VIIIJNK.Inhibitor.VIIIHLA-AHLA-Akinetin ribosidekinetin ribosideEnzalutamideEnzalutamidebrefeldin.Abrefeldin.AARN-509ARN-509sparfosic acidsparfosic acidpiperlonguminepiperlongumineAndrogenAndrogenFlutamideFlutamidePAC-1PAC-1abirateroneabirateroneindisulamindisulamAREGAREGPD0325901PD0325901NT5ENT5EMotesanibMotesanibOSI-906 (Linsitinib)OSI-906 (Linsitinib)MP470MP470KIN001-102KIN001-102XAV 939XAV 939Bleomycin (50 uM)Bleomycin (50 uM)EZH2 inhibitorEZH2 inhibitorGW441756XGW441756XEZH2 inhibitors in RAS wtEZH2 inhibitors in RAS wtPBRM1PBRM1Nutlin-3aNutlin-3aMytomycin CMytomycin CY-39983Y-39983Liposomal DoxorubicinLiposomal DoxorubicinGemcitabineGemcitabineCis-PlatinCis-PlatinTP53TP53ML 210ML 210isoevodiamineisoevodiaminelovastatin acidlovastatin acidPDMPPDMPFedratinibFedratinibTyrphostin AG 1478Tyrphostin AG 1478(1S,3R)-RSL3(1S,3R)-RSL3Fqi1Fqi1FBXW7FBXW7CDK4/6 inhibitorsCDK4/6 inhibitorsMST-312MST-312PD-0332991PD-0332991triacsin Ctriacsin C2,4-dideoxy-DC-45-A22,4-dideoxy-DC-45-A2pifithrin-mupifithrin-mutamatinibtamatinibSMR000068650SMR000068650CDKN2ACDKN2AquinoclaminequinoclaminePertuzumabPertuzumabNeratinibNeratinibERBB2 TKIsERBB2 TKIschaetocinchaetocinchemotherapychemotherapy179324-69-7179324-69-7Vorinostat (SAHA)Vorinostat (SAHA)Ado-trastuzumab emtansineAdo-trastuzumab emtansineERBB2ERBB2BRD6368BRD6368oligomycin.Aoligomycin.AERBB3ERBB3austocystin.Daustocystin.DChloropentafluorobenzeneChloropentafluorobenzeneSMARCA4SMARCA4ubistatin Bubistatin BBinimetinib (MEK162)Binimetinib (MEK162)NRASNRASPP-30PP-30CHEMBL399379CHEMBL399379docetaxel in KRAS mutantdocetaxel in KRAS mutantSarcolysinSarcolysinRegorafenibRegorafenibKRASKRASPI3K pathway inhibitors (alone or in combination)PI3K pathway inhibitors (alone or in combination)tosedostattosedostatML214ML214triptolidetriptolideBYL719 (Alpelisib)BYL719 (Alpelisib)PIK3CAPIK3CAAV-203AV-203PaclitaxelPaclitaxelCarboplatinCarboplatinPatritumabPatritumabAnti-ERBB3 AgentsAnti-ERBB3 AgentsNRG1NRG1cetuximabcetuximab

Models in Cetuximab

Loading, please wait...
Model
Level
Reference ID
Tissue
Cancer
Drug
Clinical Response
Source
No matching records found

​​​​

SITE
DATATYPES
CLASSFICATION
Map

Copyright © 2018 Modellab | All Rights Reserved

Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.